Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients  by Kim, Si-Hyun et al.
International Journal of Infectious Diseases 15 (2011) e753–e758Voriconazole-related severe adverse events: clinical application of therapeutic
drug monitoring in Korean patients§
Si-Hyun Kim a, Dong-Seok Yimb, Su-Mi Choi a, Jae-Cheol Kwon a, Seunghoon Han b, Dong-Gun Lee a,*,
Chulmin Park c, Eun-Young Kwon c, Sun Hee Park a, Jung-Hyun Choi a, Jin-Hong Yoo a
aDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
bDepartment of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, South Korea
cCatholic Research Institutes of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
A R T I C L E I N F O
Article history:
Received 17 March 2011
Received in revised form 2 June 2011
Accepted 16 June 2011
Corresponding Editor: William Cameron,
Ottawa, Canada
Keywords:
Voriconazole
Therapeutic drug monitoring
Adverse drug event
Korea
S U M M A R Y
Background: Voriconazole is a triazole agent with excellent antifungal activity against Aspergillus species.
However, despite its potential advantages, the occurrence of unpredictable toxicities might be critical in
immunocompromised patients. The aim of this study was to analyze risk factors for voriconazole-related
severe adverse events (SAEs).
Methods: This prospective observational study was conducted in Korean patients with hematological
malignancies and invasive aspergillosis on intravenous voriconazole therapy between June 2008 and
April 2009.
Results: Of the 25 patients enrolled, eight (32%) showed voriconazole-related SAEs, which included
hepatotoxicities (n = 5), cardiac tachyarrhythmias (n = 2), and neurotoxicity (n = 1). Sex, age, underlying
hematological malignancies, voriconazole dose, the co-administration of a proton pump inhibitor, and
CYP2C19 genotype were not found to be related to the occurrence of SAEs. However, trough plasma
concentrations of voriconazole were found to be signiﬁcantly higher in the patients with an SAE: median
6.32 mg/l (interquartile range (IQR) 2.86–9.71 mg/l) vs. median 2.15 mg/l (IQR 0.92–4.00 mg/l);
p = 0.011. Receiver operating characteristic curve analysis identiﬁed a cut-off trough concentration
for SAEs of 5.83 mg/l (sensitivity 62.5% and speciﬁcity 94.1%). Furthermore, multivariate analysis showed
that a trough concentration of 5.83 mg/l was the only signiﬁcant independent risk factor of an SAE.
Conclusions: This study shows that therapeutic drug monitoring is indicated in patients with a
voriconazole-related SAE and that dose adjustment is required if the trough concentration of
voriconazole exceeds 5.83 mg/l.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Aspergillus species are the most common ﬁlamentous fungal
pathogens in febrile neutropenic patients with hematological
malignancies and in hematopoietic stem cell transplantation
(HSCT) recipients.1–3 Because invasive aspergillosis is associated
with high morbidity and mortality in these patients, physicians
require an antifungal agent that is both effective and safe.
Voriconazole is currently the drug of choice for the treatment of
invasive aspergillosis, because of its excellent in vitro antifungal§ This study was presented under the title ‘‘Therapeutic drug monitoring of
voriconazole in patients with invasive aspergillosis in Korea’’ at the 47th Annual
Meeting of the Infectious Diseases Society of America, Philadelphia, PA, USA, 2009
(Abstract M-1043).
* Corresponding author. Tel.: +82 2 2258 6003; fax: +82 2 535 2494.
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doi:10.1016/j.ijid.2011.06.004activity and clinical evidence of its survival beneﬁt.4–7 As a result,
its use has markedly increased in patients with hematological
malignancies.
Voriconazole is generally well tolerated and the majority of its
adverse events are similar to those of other triazoles.8 However,
anecdotal case reports have described unexpected severe adverse
events (SAEs) related to voriconazole, such as hepatic failure and
encephalopathy,9–11 which potentially could result in serious
organ damage and negatively impact clinical outcome in patients
with hematological malignancies. Accordingly, a means of
predicting voriconazole-related SAEs is required, and early
intervention is needed to minimize negative impacts on clinical
outcome.
This study was performed to investigate voriconazole-related
SAEs and identify their risk factors in Korean patients with
hematological malignancies treated with intravenous voriconazole
for invasive aspergillosis.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study design and patients
Patients with hematological malignancies being treated with
intravenous voriconazole between June 2008 and April 2009 were
eligible for this prospective observational study. Pregnant
women, patients with an abnormal liver or renal function test
(alanine aminotransferase (ALT) or aspartate aminotransferase
(AST) more than ﬁve times the upper limit of normal; alkaline
phosphatase (ALP), g-glutamyl transpeptidase (GGT), or total
bilirubin more than three times the upper limit of normal; or
serum creatinine more than two and a half times the upper limit of
normal), and patients under 15 years of age were excluded.
Voriconazole was intravenously administered for the treatment of
probable or proven invasive aspergillosis. Invasive aspergillosis
was classiﬁed as deﬁned by the European Organization for the
Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group Consensus Group.12
After obtaining written informed consent, demographic data,
underlying disease, and clinical characteristics were recorded,
and blood samples were drawn for determining voriconazole
plasma concentration and the genotype of cytochrome P450 2C19
isoenzyme (CYP2C19). All concomitant medications during
voriconazole therapy were reviewed and drugs known to interact
with voriconazole were recorded.13–16 This study was approved
by the Institutional Review Board at Yeouido St. Mary’s Hospital
(SCMC07BR054) and registered at http://www.ClinicalTrials.gov
(NCT00673348).
2.2. Safety of voriconazole
During intravenous voriconazole therapy, all adverse events,
such as signs and symptoms, laboratory results (including
hematology and blood chemistry results; AST, ALT, ALP, GGT,
total bilirubin, serum albumin, and creatinine), and radiologic and
electrocardiographic ﬁndings were recorded, regardless of their
causal relationship with voriconazole therapy. Adverse events
were categorized and graded as described by the National Cancer
Institute, and their severities were recorded as the highest grades
achieved after initiating voriconazole therapy.17 Grades 3 through
5 are referred to as SAEs. Causal relationships between adverse
events and voriconazole therapy were assessed using the Naranjo
Probability Scale by two independent investigators and classiﬁed
as deﬁnite, probable, possible, or doubtful.18 Conﬂicting events
were reviewed by a third investigator and discrepancies were
resolved by consensus. Doubtful adverse events were not viewed
as adverse events during the analysis.
2.3. Voriconazole plasma concentrations
All patients received voriconazole intravenously at a loading
dose of 6 mg/kg administered twice on the ﬁrst day of treatment,
and this was followed by 4 mg/kg twice daily whenever possible,
according to the manufacturer’s recommendations. At least 4 days
after starting therapy, paired plasma samples were collected into
heparinized tubes (Vacutainer, BD Biosciences, Franklin Lakes, NJ,
USA), just before the next dose (trough) and 2 h after the next dose
(peak). Samples were centrifuged (3000 rpm, 4 8C, 10 min)
immediately after collection, and plasma was stored at 70 8C
until assay. Voriconazole concentrations were measured using a
high-performance liquid chromatography method based on the
report by Khoschsorur et al.19 Voriconazole was supplied by Pﬁzer
Inc. (USA), and ketoconazole, which was used as internal standard
material, was supplied by Sigma (Seoul, Korea). The quality controlsamples were prepared in 1.5 ml polypropylene tubes with the
nominal concentrations of 0.3, 4, and 16 mg/l and stored at 70 8C.
The internal standard solution (ketoconazole, 30 mg/l in 70%
methanol) was stored at 20 8C. Upon sample analysis, 100 ml of
the internal standard solution was added to 500 ml of plasma and
then brieﬂy vortexed. For extraction, 5 ml of extraction solvent n-
heptane–isoamyl alcohol (90:10 (vol/vol)) was added; the tubes
were vortexed for 30 s and then centrifuged (3000 rpm, 4 8C,
10 min). The organic layer was transferred into a glass tube and
evaporated to dryness at 50 8C under a gentle stream of nitrogen
gas (run time: 90 min). The residue was reconstituted with 150 ml
of mobile phase, vortexed, transferred into a 1.5-ml polypropylene
tube and centrifuged (12 000 rpm, 4 8C, 10 min). The supernatant
was ﬁnally used for injection. Chromatographic separation was
performed on a hydrosphere C18 column (5 mm particle size,
250  4.6 mm, Phenomenex, Torrance, CA, USA) maintained at
40 8C. The mobile phase which was composed of 0.05 M phosphate
buffer (pH 6.0), acetonitrile, and methanol (35:45:20 (vol/vol/vol))
was supplied at a ﬂow rate of 1.7 ml/min. The detection
wavelength was at 255 nm (for both ketoconazole and voricona-
zole), and the injected volume was 50 ml. The retention times were
2.56 min for voriconazole and 4.97 min for ketoconazole. The
range of quantiﬁcation was 0.1–20 mg/l with the correlation
coefﬁcient 0.9989. The intra- and inter-day precision (less than
10% coefﬁcient of variation) and accuracy (95.9–101.9%) were
acceptable.
2.4. Genotyping of CYP2C19 alleles
Genomic DNA was extracted from plasma specimens using a
QIAamp Blood kit (Qiagen, Chatsworth, CA, USA) as described by
Dixon et al.20 Genotyping of the CYP2C19*2 and CYP2C19*3 alleles
was performed as described by Goldstein and Blaisdell by Sma I
restriction fragment length polymorphism (RFLP), and by De
Morais et al. by BamH I RFLP.21,22 The presence of CYP2C19*1 was
inferred from the absence of the *2 and *3 alleles.
Polymorphisms of CYP2C19 were classiﬁed as follows: exten-
sive metabolizers (EM, CYP2C19*1/*1), heterozygous extensive
metabolizers (HEM, CYP2C19*1/*2 or *1/*3), and poor metabolizers
(PM, CYP2C19*2/*2, *2/*3, or *3/*3). The EM genotype was viewed as
wild and all other genotypes as mutant.
2.5. Statistical analysis
The Chi-square test or Fisher’s exact test was used to compare
categorical variables, and the Mann–Whitney U-test or Kruskal–
Wallis test was used to compare continuous variables. When one of
the cells in two-by-two contingency tables was equal to zero, the
odds ratio (OR) was estimated via penalized maximum likelihood
test.23 Correlation analysis was performed using the Spearman
test. The cut-off value of the trough concentration of voriconazole
for SAEs was derived by receiver operating characteristic (ROC)
curve analysis. Multivariate logistic regression analysis was
performed to identify the risk factors for SAEs. Variables with p-
values of <0.25 by univariate analysis were entered into the
multivariable model.24 Two-sided p-values of <0.05 were consid-
ered statistically signiﬁcant.
3. Results
3.1. Patients
During the study period, 25 adult patients were consecutively
enrolled in the study. Demographic and clinical characteristics are
summarized in Table 1. Acute leukemia (80%, 20/25), including
acute myelogenous and lymphocytic leukemia, was the most
Table 1
Demographic and clinical characteristics of the study subjects (N = 25)
Characteristic n (%) or median (IQR)
Sex, male 12 (48)
Age (years) 45 (38–54)
Underlying hematological malignancies
Acute myelogenous leukemia 14 (56)
Acute lymphocytic leukemia 6 (24)
Myelodysplastic syndrome 2 (8)
Chronic myelogenous leukemia 2 (8)
Non-Hodgkin’s disease 1 (4)
Host factors for invasive aspergillosis
Neutropeniaa 20 (80)
Receiving an allogeneic HSCT 2 (8)
Post-allogeneic HSCT with GVHD 3 (12)
Genotype of CYP2C19
EM 6 (24)
HEM 17 (68)
PM 2 (8)
Voriconazole daily dose (mg/kg/day)
Loading 12.0 (11.4–12.5)
Maintenance 7.7 (7.1–8.3)
Duration of intravenous voriconazole therapy (days) 8 (7–14)
IQR, interquartile range; HSCT, hematopoietic stem cell transplantation; GVHD,
graft-versus-host disease; EM, extensive metabolizer; HEM, heterozygous exten-
sive metabolizer; PM, poor metabolizer.
a An absolute neutrophil count of <0.5  109 cells/l or a count of <1  109 cells/l
with a predicted decrease to <0.5  109 cells/l.
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present in six patients (24%). Mutant types were as follows:
CYP2C19*1/*2 (n = 9), *1/*3 (n = 8), *2/*2 (n = 1), and *3/*3 (n = 1).
The cytochrome P450 isoenzyme-interacting medications were:
proton pump inhibitors (n = 12), calcium channel blockers (n = 11),
benzodiazepines (n = 9), methylprednisolone (n = 6), oral contra-
ceptives (n = 4), and cyclosporine or tacrolimus (n = 3). Of these,
only the proton pump inhibitors (lansoprazole (n = 3) and
rabeprazole (n = 9)) were capable of altering the voriconazole
concentration. No patient had chronic liver disease.
3.2. Adverse events
The most common adverse event was an abnormal liver
function test (48%, 12/25), followed by diarrhea (20%, 5/25), rash
(16%, 4/25), visual disturbance (12%, 3/25), and vomiting (4%, 1/
25). No patient who developed nephrotoxicity had a decrease in
glomerular ﬁltration rate of 25% from baseline or required renal
replacement therapy. Voriconazole-related SAEs were observed in
eight (32%) of the 25 patients (Table 2), and included hepatotoxi-
cities (n = 5), cardiac toxicities (n = 2), and neurotoxicity (n = 1).
The patterns of abnormal liver function tests were cholestatic
(n = 3), hepatic (n = 1), or mixed (n = 1). Two patients with an
episode of cardiac toxicity had a prolonged QT interval before
starting voriconazole therapy (corrected QT interval, 0.48 s and
0.45 s, respectively). However, no increase in QT interval was
observed in these patients during voriconazole therapy. These two
patients were on a concomitant benzothiazepine calcium channel
blocker (verapamil and diltiazem, respectively) to treat hyperten-
sion, but did not experience heart failure or any other structural
abnormality by transthoracic echocardiography. Toxic encepha-
lopathy developed in one patient who was not taking any drug
capable of interacting with voriconazole. Unfortunately, the
modiﬁcation of voriconazole therapy and clinical course of this
neurotoxicity was not determined due to discharge from hospital 2
days after the occurrence of neurotoxicity and loss to follow-up.
After the occurrence of an SAE, the voriconazole daily dose was
reduced in three patients, and two patients switched to oral
therapy. Two patients discontinued voriconazole therapy due to
SAEs. In one of these two patients (patient 1), supraventriculartachycardia completely resolved the day after discontinuing
voriconazole, and the other (patient 7) required discontinuation
of voriconazole because of severe hepatotoxicity deemed to be
probably related, but ﬁnally died from hepatic failure 11 days after
discontinuation.
3.3. Therapeutic drug monitoring
The median time from starting voriconazole therapy to the
measurement of plasma concentration was 6 days (interquartile
range (IQR) 5–7.5 days). Median trough and peak concentrations
(IQR) were 2.93 mg/l (1.59–5.82 mg/l) and 4.76 mg/l (2.60–
7.80 mg/l), respectively. Trough concentrations of <1 mg/l were
detected in four (16%) patients and of 6 mg/l in ﬁve (20%)
patients. A strong linear correlation was found between trough and
peak concentrations according to the equation: peak levels (mg/l) =
1.378 + 1.00  trough levels (mg/l) (R2 = 0.958, p < 0.001).
Trough concentrations were not found to depend on CYP2C19
genotype, and median trough concentrations (IQR) were 2.12 mg/l
(1.70–5.68 mg/l), 3.76 mg/l (0.92–6.96 mg/l), and 2.75 mg/l (2.55
and 2.94 mg/l) in patients with EM (n = 6), HEM (n = 17), and PM
(n = 2), respectively (p = 0.859).
3.4. Risk factors for voriconazole-related SAEs
The patients who experienced an SAE had a signiﬁcantly higher
trough concentration (median 6.32 mg/l (IQR 2.86–9.71 mg/l))
than patients who did not (median 2.15 mg/l (IQR 0.92–4.00 mg/l))
(p = 0.011). During subgroup analysis, patients with cardiac
toxicities (n = 2) showed a signiﬁcantly higher trough concentra-
tion (median 9.15 mg/l (8.05 and 10.26 mg/l, respectively) vs.
2.55 mg/l (IQR 1.37–5.63 mg/l); p = 0.027). A ROC curve analysis of
trough concentrations with respect to the occurrence of an SAE
was also performed (Figure 1), and the area under the curve
(mean  SD) was 0.82  0.09 (95% conﬁdence interval (CI) 0.63–1.00;
p = 0.012). Furthermore, a trough concentration cut-off value of
5.83 mg/l was found to have a sensitivity of 62.5% and a speciﬁcity of
94.1% for an SAE. No other demographic or clinical parameter was
found to be related to an SAE by univariate analysis (Table 3). In
addition, the three CYP2C19 genotypes were found to be no different
in terms of SAE frequencies. Multivariate logistic regression analysis
demonstrated that a trough concentration of 5.83 mg/l was
independently associated with an SAE (adjusted OR 7.745, 95% CI
1.064–93.570; p = 0.043) (Table 3).
4. Discussion
In this study, voriconazole-related SAEs and risk factors were
evaluated in 25 consecutive Korean patients with hematological
malignancies and invasive aspergillosis. Eight patients experi-
enced an SAE: hepatotoxicity in ﬁve, cardiac toxicity in two, and
neurotoxicity in one patient. A voriconazole trough plasma
concentration of 5.83 mg/l was the only independent risk factor
found to be associated with an SAE.
We report the experience with therapeutic drug monitoring of
intravenous voriconazole therapy. Voriconazole pharmacokinetics
could be affected by changes from intravenous to oral therapy. In
one investigation on intravenous-to-oral switchover, maximum
plasma concentrations following oral dosing were lower than
those obtained following intravenous administration, ranging
from 63% to 90%. However, there was no signiﬁcant difference in
pharmacokinetic parameters, including the volume of distribution,
clearance of voriconazole, and elimination rate constant, between
voriconazole administration routes.25 These ﬁndings suggest that
pharmacokinetic data during oral voriconazole therapy could be
estimated from that during intravenous therapy.
Table 2
Characteristics and clinical courses of patients who experienced a severe adverse event related to intravenous voriconazole therapy
Patient No. Age
(years)
Sex Voriconazole
daily dose
(mg/kg/day)
CYP2C19
genotype
Voriconazole
concentration
(mg/l)
SAE Dose adjustment Clinical assessment at 6 weeks from
the start of voriconazole therapy
Trough Peak Category (severity) Relation SAE Outcome
1a,b 58 F 8.6 HEM 8.05 8.62 Cardiac toxicity;
supraventricular tachycardia (grade 3)
Probable Discontinuation Complete resolution Survived
2 49 M 6.8 PM 2.55 3.52 Neurotoxicity; toxic encephalopathy (grade 3) Possible No adjustment NA Loss to follow-up
3 55 F 8.5 EM 1.81 3.55 Hepatotoxicity; elevation of ALT, ALP,
GGT (grade 3)
Possible Switch to oral therapy Partial resolution Survived
4a 63 M 8.2 HEM 10.26 10.24 Cardiac toxicity; ventricular
tachycardia (grade 4)
Possible Dose reduction Complete resolution Survived
5 21 M 7.6 HEM 6.79 8.55 Hepatotoxicity; elevation of GGT (grade 3) Possible Dose reduction Partial resolution Survived
6b 35 F 8.2 HEM 5.84 7.39 Hepatotoxicity; elevation of ALP (grade 3) Possible Switch to oral therapy Complete resolution Died from refractory
leukemia
7b 38 M 8.0 HEM 15.62 16.67 Hepatotoxicity; elevation of GGT (grade 5) Probable Discontinuation NA Died from
hepatic failure
8b 24 M 6.0 HEM 3.76 5.62 Hepatotoxicity; elevation of AST, ALT (grade 3) Probable Dose reduction Complete resolution Died from alveolar
hemorrhage
SAE, severe adverse event; F, female; M, male; HEM, heterozygous extensive metabolizer; PM, poor metabolizer; EM, extensive metabolizer; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, g-glutamyl
transpeptidase; AST, aspartate aminotransferase; NA, not available.
a Concomitant administration of benzothiazepine calcium channel blocker (diltiazem in patient 1 and verapamil in patient 4).
b Concomitant administration of proton pump inhibitor (all rabeprazole).
Table 3
Risk factors of severe adverse events related to intravenous voriconazole therapy
n SAE (n=8),
n (%)
OR (95% CI) p-Value Adjusted ORa (95% CI) p-Value
Sex, male 12 5 (42) 2.381 (0.423–13.387) 0.411 - -
Age 55 years 6 3 (50) 2.800 (0.419–18.689) 0.344 - -
Underlying hematological malignancy,
acute leukemia
20 8 (40) 7.480 (0.690–1030.940) 0.108b 13.272 (0.719–2578.650) 0.090b
Risk for IA, HSCT 5 2 (40) 1.556 (0.205–11.829) 1.000 - -
Maintenance dose of voriconazole 8 mg/kg/day 10 5 (50) 4.000 (0.681–23.512) 0.194 2.557 (0.323–21.150) 0.361b
Co-medication, proton pump inhibitor 12 4 (33) 1.125 (0.209–6.046) 1.000 - -
Genotype of CYP2C19 - -
HEM or PM (vs. EM) 19 7 (37) 2.917 (0.281–30.298) 0.624 - -
PM (vs. EM or HEM) 2 1 (50) 2.286 (0.124–41.985) 1.000 - -
Trough concentration 5.83 mg/l 7 5 (71) 12.500 (1.600–97.647) 0.017 7.745 (1.064–93.570) 0.043b
SAE, severe adverse event; OR, odds ratio; CI, conﬁdence interval; NA, not available; IA, invasive aspergillosis; HSCT, hematopoietic stem cell transplantation; HEM, heterozygous extensive metabolizer; PM, poor metabolizer; EM,
extensive metabolizer.
a Binary logistic regression using the enter method (Chi-square = 9.070; p=0.028).
b Penalized maximum likelihood test.
S.-H
.
 K
im
 et
 a
l.
 /
 In
tern
a
tio
n
a
l
 Jo
u
rn
a
l
 o
f
 In
fectio
u
s
 D
isea
ses
 1
5
 (2
0
1
1
)
 e7
5
3
–
e7
5
8
e7
5
6
Figure 1. Receiver operating characteristic curve for voriconazole trough
concentrations with regard to an occurrence of severe adverse events (AUC, area
under the curve).
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voriconazole plasma concentration and visual disturbance, hepato-
toxicity, and neurotoxicity.10,11,26–29 Cardiac toxicity has been
shown to be associated with voriconazole administration in dogs,
but human studies on the topic are limited.30,31 In the present study,
two patients developed cardiac tachyarrhythmia. Both had recently
received anthracycline-based chemotherapy for acute myelogenous
leukemia and had grade 1 hypokalemia when the arrhythmia
developed. In addition, they were on concomitant benzothiazepine
calcium channel blockers, which may have contributed to cardiac
dysrhythmia including PR prolongation, AV block, transient episodes
of junctional escape rhythm, AV dissociation, and atrial ﬁbrillation,
but not to QT prolongation.32,33 Voriconazole trough concentrations
had extremely high values in these two patients. These ﬁndings
suggest a signiﬁcant association between cardiac toxicities and
voriconazole plasma concentration, particularly in patients with
other factors known to inﬂuence cardiac rhythm.
Based on in vitro susceptibility data (minimum inhibitory
concentration (MIC)90 0.5–1 mg/l for Aspergillus spp.) and a free-
circulating fraction of 40–50%, a value of 1 mg/l was chosen as the
lower cut-off value for voriconazole trough concentration.11,34,35 In
the present study, SAEs were observed in a signiﬁcantly higher
proportion of patients with a trough concentration of 5.83 mg/l.
Accordingly, we suggest that the optimum therapeutic range of the
trough concentration of voriconazole in Korean patients is 1–
5.83 mg/l, which is consistent with the results of several studies
conducted on the correlation between voriconazole concentration
and toxicities and expert opinions on the therapeutic range of
voriconazole.11,14,27,36–38
The distributions of CYP2C19 genotypes vary in different racial
groups. Generally, Asians, including the Japanese and Chinese,
have a higher proportion of PM than Caucasians (approximately
14% to 19% in Asians and 2% to 5% in Caucasians).30 The frequencies
of EM and HEM found in the present study (24% and 68%,
respectively) were similar to those reported in other Asian
populations, but the frequency of PM was relatively low
(approximately 8%). Genetic polymorphisms of CYP2C19 result
in different rates of voriconazole metabolism, that is, 4- and 2-fold
higher voriconazole concentrations are found in patients with PMand HEM, respectively, as compared with patients with EM.
However, we found no relationship between CYP2C19 genotypes
and voriconazole plasma concentrations or the development of
SAEs, which concurs with the ﬁndings of Ikeda et al.39 Too few
patients with PM and large inter-individual variability of trough
concentration might be responsible for the lack of power. Also,
these ﬁndings are probably explained by a combination of factors
known to impact the pharmacokinetics of voriconazole, such as,
age, gender, hepatic function, and the activity of CYP isoenzymes
other than CYP2C19.8,14,15 Furthermore, interactions with other
drugs that share the hepatic metabolic pathway of voriconazole
might markedly alter voriconazole metabolism in patients with
hematological malignancies undergoing intensive chemotherapy
or HSCT recipients.
Our study has the limitations of a small sample size and the
non-serial monitoring of voriconazole concentration. However,
this is the ﬁrst report to be issued on the risk factors of
voriconazole-related toxicity. Furthermore, our ﬁndings suggest
a therapeutic range for voriconazole trough concentration in
Korean patients and a relationship between voriconazole plasma
concentration and cardiac toxicity.
We conclude that patients administered voriconazole intrave-
nously require careful monitoring for SAEs, and that such
monitoring should include liver function tests, cardiac rhythm,
and neurologic changes related to elevated voriconazole plasma
concentrations. If a voriconazole-related SAE is suspected, the
monitoring of voriconazole plasma trough concentrations may
offer a practical means of assessing the appropriate voriconazole
dose. A study on the impact of therapeutic dose adjustment on
voriconazole plasma concentration and toxicity is required to
conﬁrm our ﬁndings.
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